Nafithromycin

Drug Profile

Nafithromycin

Alternative Names: WCK 4873

Latest Information Update: 22 Feb 2017

Price : $50

At a glance

  • Originator Wockhardt
  • Class Antibacterials; Hexoses; Ketolides; Lactones; Pyridines; Thiadiazoles
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Community-acquired pneumonia

Most Recent Events

  • 16 Sep 2016 Wockhardt plans a phase II trial for Community-acquired pneumonia in USA, Bulgaria, Latvia, Georgia, Romania, Russia, South Africa, Serbia and Montenegro (PO) (NCT02903836)
  • 01 Sep 2016 Phase-II clinical trials in Community-acquired pneumonia in Latvia, Bulgaria, USA (PO) (EudraCT2016-001246-26) (NCT02903836)
  • 26 Aug 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top